The EGFR tyrosine kinase inhibitor tyrphostin AG-1478 causes hypomagnesemia and cardiac dysfunction

Authors

William B. Weglicki, George Washington University
Jay H. Kramer, George Washington University
Christopher F. Spurney, Children's National Medical Center, Washington, DCFollow
Joanna J. Chmielinska, George Washington University
I. Tong Mak, George Washington UniversityFollow

Document Type

Journal Article

Publication Date

8-2012

Journal

Canadian Journal of Physiology and Pharmacology

Volume

Volume 90, Issue 8

Inclusive Pages

1145-1149

Keywords

Echocardiography--drug effects; Enzyme Inhibitors--adverse effects; Protein-Tyrosine Kinases--antagonists & inhibitors; Quinazolines--adverse effects; Receptor; Epidermal Growth Factor--antagonists & inhibitors; Renal Tubular Transport; Inborn Errors--chemically induced; Tyrphostins--adverse effects

Comments

This is an open access PubMed Central article. Click on link for full-text access.

APA Citation

Weglicki, W., Kramer, J., Spurney, C., Chmielinska, J., & Mak, I. (2012). The egfr tyrosine kinase inhibitor tyrphostin ag-1478 causes hypomagnesemia and cardiac dysfunction. Canadian Journal of Physiology and Pharmacology, 90(8), 1145-1149.

Peer Reviewed

1

Open Access

1